GLUD1 and cancer: Glutaminolysis is essential for the proliferation of cancer cells, thus inhibiting glutamine transporter SLC1A5 with almonertinib and/or V9302, and downregulating GLUD1 with OSC is a potential therapeutic approach for NSCLC.